Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Immunome, Inc.

Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.

For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.

Investor Contact Corleen Roche Chief Financial Officer investors@immunome.com

Media Contact Andrew W. Mielach LifeSci Communications amielach@lifescicomms.com

Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more Immunome Charts.
Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more Immunome Charts.